Search

everythinglearnresearchcommunity

for

Search:↓

Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Nab-paclitaxel is as effective as cisplatin but safer for early-stage cervical cancer treatment.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

A new microneedle patch significantly improves melanoma treatment by using a special material to activate cancer-fighting drugs and disrupt cancer cells.

FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.

Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

A new treatment may prevent hair loss from chemotherapy by normalizing scalp cell death and reducing inflammation.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Cancer treatments targeting specific cells often cause skin problems, which can affect how much medicine patients can take.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Immune checkpoint inhibitors used in cancer therapy can cause hair loss, and understanding this can help manage the side effect.

Tislelizumab can cause cutaneous lupus erythematosus.

Basal cell carcinomas may use IDO to protect themselves from the immune system.

Kenikir leaf extract nanosuspension may help inhibit breast cancer cell growth.

Tofacitinib helped regrow hair in a woman with alopecia areata.

Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.